<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003375</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-9802</org_study_id>
    <secondary_id>CDR0000066367</secondary_id>
    <secondary_id>E-R9802</secondary_id>
    <secondary_id>NCCTG-R9802</secondary_id>
    <secondary_id>SWOG-R9802</secondary_id>
    <nct_id>NCT00003375</nct_id>
  </id_info>
  <brief_title>Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma</brief_title>
  <official_title>A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. It is not yet known whether radiation therapy combined with chemotherapy is more&#xD;
      effective than radiation therapy alone in treating patients with low-grade glioma.&#xD;
&#xD;
      PURPOSE: Phase II/III trial to evaluate observation and to compare the effectiveness of&#xD;
      radiation therapy with or without combination chemotherapy in treating patients with&#xD;
      low-grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify the overall survival of low-risk adult patients with supratentorial low-grade&#xD;
           glioma who are observed postoperatively.&#xD;
&#xD;
        -  Compare the overall survival of high-risk adult patients with supratentorial low-grade&#xD;
           glioma who receive postoperative external beam radiotherapy with or without&#xD;
           procarbazine, lomustine, and vincristine (PCV) chemotherapy.&#xD;
&#xD;
        -  Compare the toxic effects of postoperative radiotherapy with or without PCV chemotherapy&#xD;
           in patients with unfavorable low-grade glioma.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to tumor subtype&#xD;
      (astrocytoma [mixed-astro dominant or equal astro/oligo mix] vs oligodendroglioma&#xD;
      [mixed-oligo dominant]), age (younger than 40 vs at least 40), Karnofsky performance status&#xD;
      (60-80% vs 90-100%), and contrast enhancement on preoperative scan (present vs absent).&#xD;
      Patients with low-risk disease (younger than 40 years old whose tumors have been surgically&#xD;
      removed) are assigned to arm I. Patients with high-risk disease (at least 40 years old or who&#xD;
      have had incomplete tumor removal) are randomized to arm II or III.&#xD;
&#xD;
        -  Arm I (low-risk patients): Patients are observed. Patients may receive treatment if&#xD;
           tumor recurs.&#xD;
&#xD;
        -  Arm II (high-risk patients): Patients receive daily external beam radiotherapy 5 days a&#xD;
           week for 6 weeks.&#xD;
&#xD;
        -  Arm III (high-risk patients): Patients receive radiotherapy as in arm II followed by&#xD;
           chemotherapy 1 month later. Chemotherapy consists of oral lomustine on day 1,&#xD;
           vincristine IV on days 8 and 29, and oral procarbazine on days 8-21. Each course of&#xD;
           chemotherapy lasts 8 weeks. Patients may receive up to 6 courses of chemotherapy.&#xD;
&#xD;
      Patients are followed every 4 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 252 patients will be accrued within 5.25 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">May 14, 2018</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 5 years or 80 deaths have been reported.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization to the date of progression, death or last follow-up. Analysis ours at the same time as the primary outcome analysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severe or worse toxicities (&gt;= grade 3) of unfavorable patients</measure>
    <time_frame>From start of treatment to end of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation plus PCV chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
    <arm_group_label>Radiation plus PCV chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
    <arm_group_label>Radiation plus PCV chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Radiation plus PCV chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Radiation plus PCV chemotherapy</arm_group_label>
    <arm_group_label>Radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed unifocal or multifocal supratentorial WHO grade II&#xD;
             astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic), oligodendroglioma, or&#xD;
             oligoastrocytoma&#xD;
&#xD;
          -  Patients with neurofibromatosis are eligible&#xD;
&#xD;
          -  No other low-grade histologies, including:&#xD;
&#xD;
               -  Pilocytic astrocytoma&#xD;
&#xD;
               -  Subependymal giant cell astrocytoma of tuberous sclerosis&#xD;
&#xD;
               -  Subependymoma&#xD;
&#xD;
               -  Pleomorphic xanthoastrocytoma&#xD;
&#xD;
               -  Presence of a neuronal element such as ganglioglioma&#xD;
&#xD;
               -  Dysneuroembryoplastic epithelial tumor&#xD;
&#xD;
          -  No presence of any high-grade glioma, including:&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic oligoastrocytoma&#xD;
&#xD;
          -  No tumors in nonsupratentorial or other locations including optic chiasm, optic&#xD;
             nerve(s), pons, medulla, cerebellum, or spinal cord&#xD;
&#xD;
          -  No evidence of spread to spinal meninges or noncontiguous cranial meninges (i.e.,&#xD;
             leptomeningeal gliomatosis)&#xD;
&#xD;
          -  No gliomatosis cerebri&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  For high-risk patients:&#xD;
&#xD;
               -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
               -  Platelet count normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times normal&#xD;
&#xD;
          -  SGOT or SGPT no greater than 4 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times normal&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No chronic lung disease (unless DLCO at least 60%)&#xD;
&#xD;
        Neurological:&#xD;
&#xD;
          -  Neurologic function score no greater than 3&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             nonmelanoma skin cancer&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the head or neck (unless brain is clearly excluded, such as&#xD;
             radiotherapy for localized vocal cord cancer)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward G. Shaw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffrey R. Barger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan C. Buckner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minesh P. Mehta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <results_reference>
    <citation>Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol. 2014 Feb 20;32(6):535-41. doi: 10.1200/JCO.2013.53.1830. Epub 2014 Jan 13.</citation>
    <PMID>24419119</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012 Sep 1;30(25):3065-70. doi: 10.1200/JCO.2011.35.8598. Epub 2012 Jul 30.</citation>
    <PMID>22851558</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008 Nov;109(5):835-41. doi: 10.3171/JNS/2008/109/11/0835.</citation>
    <PMID>18976072</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaw EG, Wang S, Coons S, et al.: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). [Abstract] J Clin Oncol 26 (Suppl 15): A-2006, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Shaw EG, Berkey B, Coons SW, et al.: Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). [Abstract] J Clin Oncol 24 (Suppl 18): A-1500, 2006.</citation>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

